Page 100 - ARNM-3-1

Advances in Radiotherapy &

Nuclear Medicine

SHORT COMMUNICATION
Positron emission tomography/computed

tomography in B-cell non-Hodgkin’s lymphoma
at Hanoi Oncology Hospital

Phuong Pham Cam 1,2,3 , Thai Pham Van * , Thang Nguyen Van 4 ,
1,3
and Nien Vu Thi 2
1 The Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi, Vietnam
2 Department of Oncology and Nuclear Medicine, University of Medicine and Pharmacy, Vietnam
National University, Hanoi, Vietnam
3 Department of Nuclear Medicine, Hanoi Medical University, Hanoi, Vietnam
4 Department of Nuclear Medicine, Hanoi Oncology Hospital, Hanoi, Vietnam

Abstract
This study aimed to review 18 fluoro-2-deoxy-d-glucose positron emission
tomography/computed tomography ( FDG PET/CT) imaging characteristics of B-cell
18
non-Hodgkin’s lymphoma (NHL) at Hanoi Oncology Hospital. PET/CT helps accurately
assess the NHL stage compared with other diagnostic imaging methods, such as CT
and magnetic resonance imaging. In this retrospective descriptive study, 86 newly
*Corresponding author: diagnosed B-cell NHL cases were histopathologically and immunohistochemically
Thai Pham Van examined at Hanoi Oncology Hospital between January 2018 and December 2022.
(phamvanthai@hmu.edu.vn) Patients underwent FDG PET/CT for pretreatment staging. The stages before and
18
Citation: Cam PP, Van TP, after PET/CT were evaluated and compared. Before PET/CT, 26 (30.2%), 29 (33.7%),
Van TN, Thi NV. Positron emission 15 (17.5%), and 16 (18.6%) patients were in stages I, II, III, and IV, respectively. After
tomography/computed tomography
in B-cell non-Hodgkin’s lymphoma PET/CT, the rates of Stage I, II, III, and IV cases were 22.1%, 26.8%, 20.9%, and 30.2%,
at Hanoi Oncology Hospital. respectively. PET/CT results increased the stage in 21/86 patients (24.4%). The
Adv Radiother Nucl Med. proportion of patients with advanced stages after PET/CT in the rapidly progressing
2025;3(1):92-96.
doi: 10.36922/arnm.4813 histopathology group was higher (25%) than the slowly progressing histopathology
group (21.4%), and the difference was not significant. Therefore, PET/CT is critical for
Received: September 10, 2024
accurately determining the disease stage of B-cell NHL, thereby helping to detect
Revised: October 17, 2024 additional lesions missed by conventional imaging diagnostic tools.
Accepted: November 8, 2024
18
Published online: December 9, Keywords: B-cell non-Hodgkin’s lymphoma; FDG PET/CT; Pre-PET/CT stage;
2024 Post-PET/CT stage
Copyright: © 2024 Author(s).
This is an Open-Access article
distributed under the terms of the
Creative Commons Attribution 1. Introduction
License, permitting distribution,
and reproduction in any medium, Non-Hodgkin’s lymphoma (NHL) is a group of malignant lymphoproliferative diseases
provided the original work is
properly cited. with complex clinical manifestations, histopathology, and prognosis. According to
GLOBOCAN 2022, NHL ranks 10 in Vietnam concerning new incidence among
th
Publisher’s Note: AccScience
Publishing remains neutral with common cancers, of which B-cell lymphoma accounts for most of the cases. 1
regard to jurisdictional claims in
published maps and institutional The cancer stage must be assessed for appropriate treatment. The NHL diagnosis
affiliations is based on clinical examination and paraclinical tests such as biopsy for pathology,

Volume 3 Issue 1 (2025) 92 doi: 10.36922/arnm.4813